Amgen [AMGN] vs Pfizer [PFE] Detailed Stock Comparison

Amgen Inc.

NASDAQ
Loading...

Pfizer Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amgen Inc. wins in 10 metrics, Pfizer Inc. wins in 11 metrics, with 0 ties. Pfizer Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amgen Inc. Pfizer Inc. Better
P/E Ratio (TTM) 24.22 19.61 Pfizer Inc.
Price-to-Book Ratio 21.46 1.75 Pfizer Inc.
Debt-to-Equity Ratio 640.28 77.96 Pfizer Inc.
PEG Ratio 0.22 -0.04 Amgen Inc.
EV/EBITDA 13.97 8.01 Pfizer Inc.
Profit Margin (TTM) 20.98% 12.42% Amgen Inc.
Operating Margin (TTM) 30.55% 23.95% Amgen Inc.
EBITDA Margin (TTM) 30.55% 23.95% Amgen Inc.
Return on Equity 106.10% 8.89% Amgen Inc.
Return on Assets (TTM) 7.93% 5.68% Amgen Inc.
Free Cash Flow (TTM) $8.10B $9.08B Pfizer Inc.
Dividend Yield 3.30% 6.71% Pfizer Inc.
1-Year Return 20.32% 6.81% Amgen Inc.
Price-to-Sales Ratio (TTM) 5.06 2.42 Pfizer Inc.
Enterprise Value $232.21B $206.00B Amgen Inc.
EV/Revenue Ratio 6.32 3.29 Pfizer Inc.
Gross Profit Margin (TTM) 69.84% 69.97% Pfizer Inc.
Revenue per Share (TTM) $68 $11 Amgen Inc.
Earnings per Share (Diluted) $14.24 $1.36 Amgen Inc.
Beta (Stock Volatility) 0.47 0.39 Pfizer Inc.
Short % of Float 2.60% 2.33% Pfizer Inc.

Amgen Inc. vs Pfizer Inc. Stock Performance Analysis

Loading Price Chart...

AMGN
PFE

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%
Pfizer Inc.-0.80%1.48%2.65%-2.29%-1.63%3.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%
Pfizer Inc.6.81%-34.57%-32.47%-19.28%36.37%17.90%

Performance & Financial Health Analysis: Amgen Inc. vs Pfizer Inc.

MetricAMGNPFE
Market Information
Market Cap i$187.93B$153.59B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,431,75330,662,931
90 Day Avg. Volume i2,596,29136,790,755
Last Close$350.53$26.00
52 Week Range$267.83 - $391.29$23.11 - $28.75
% from 52W High-10.42%-9.57%
All-Time High$391.29 (Mar 02, 2026)$61.71 (Dec 20, 2021)
% from All-Time High-10.42%-57.87%
Growth Metrics
Quarterly Revenue Growth0.09%-0.01%
Quarterly Earnings Growth1.13%-0.01%
Financial Health
Profit Margin (TTM) i0.21%0.12%
Operating Margin (TTM) i0.31%0.24%
Return on Equity (TTM) i1.06%0.09%
Debt to Equity (MRQ) i640.2877.96
Cash & Liquidity
Book Value per Share (MRQ)$16.07$15.21
Cash per Share (MRQ)$16.94$2.39
Operating Cash Flow (TTM) i$9.96B$11.70B
Levered Free Cash Flow (TTM) i$7.50B$13.43B
Dividends
Last 12-Month Dividend Yield i3.30%6.71%
Last 12-Month Dividend i$12.18$1.72

Valuation & Enterprise Metrics Analysis: Amgen Inc. vs Pfizer Inc.

MetricAMGN (Apr 24, 2026)PFE (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i24.2219.61
Forward P/E i14.779.48
PEG Ratio i0.22-0.04
Price to Sales (TTM) i5.062.42
Price to Book (MRQ) i21.461.75
Market Capitalization
Market Capitalization i$187.93B$153.59B
Enterprise Value i$232.21B$206.00B
Enterprise Value Metrics
Enterprise to Revenue i6.323.29
Enterprise to EBITDA i13.978.01
Risk & Other Metrics
Beta i0.470.39
Book Value per Share (MRQ) i$16.07$15.21

Financial Statements Comparison: Amgen Inc. vs Pfizer Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMGN (2025)PFE (2025)
Revenue/Sales i36.75B62.58B
Cost of Goods Sold i12.04B16.07B
COGS % of Revenue i32.8%25.7%
Gross Profit i24.71B46.51B
Gross Margin i67.2%74.3%
Research & Development i7.27B10.44B
Operating Income (EBIT) i9.08B17.41B
Operating Margin i24.7%27.8%
EBITDA i16.90B25.75B
EBITDA Margin i46.0%41.1%
Pre-Tax Income i8.98B7.52B
Pre-Tax Income % of Revenue i24.4%12.0%
Income Tax i1.27B-266.00M
Income Tax % of Revenue i3.4%-0.4%
Net Income (Profit) i7.71B7.81B
Profit Margin i21.0%12.5%

Balance Sheet & Liquidity Metrics

MetricAMGN (2025)PFE (2025)
Cash & Equivalents i9.13B1.14B
Total Current Assets i29.06B42.90B
Total Current Assets % of Revenue i79.1%68.6%
Total Current Liabilities i25.49B36.98B
Total Current Liabilities % of Revenue i69.4%59.1%
Long-Term Debt i50.01B60.81B
Long-Term Debt % of Revenue i136.1%97.2%
Total Shareholders Equity i8.66B86.78B
Retained Earnings i-25.11B114.61B
Retained Earnings % of Revenue i-68.3%183.1%
Property, Plant & Equipment i5.22B0

Cash Flow Statement Comparison

MetricAMGN (2025)PFE (2025)
Operating Cash Flow i10.51B6.43B
Operating Cash Flow % of Revenue i28.6%10.3%
Capital Expenditures i-1.86B-2.63B
Free Cash Flow i8.10B9.08B
FCF Margin i22.0%14.5%
Debt Repayment i-5.00B-9.75B
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricAMGNPFE
Shares Short i13.98M132.47M
Short Ratio i5.433.17
Short % of Float i2.60%2.33%
Shares Outstanding i538.80M5.69B
Float Shares i537.62M5.68B
% Held by Insiders i0.22%0.10%
% Held by Institutions i85.36%68.38%
% Held by Public i14.42%31.52%

Dividend Analysis & Yield Comparison: Amgen Inc. vs Pfizer Inc.

MetricAMGNPFE
Last 12-Month Dividend i$12.18$1.72
Last 12-Month Dividend Yield i3.30%6.71%
3-Year Avg Annual Dividend i$9.98$1.69
3-Year Avg Dividend Yield i0.77%1.54%
3-Year Total Dividends i$29.95$5.06
Ex-Dividend DateMay 15, 2026Jan 23, 2026